JP MORGAN 2013: Orexigen could benefit from third place finish in obesity race
This article was originally published in Scrip
Executive Summary
Hindsight may be 20/20 for Orexigen Therapeutics, whose president and CEO Michael Narachi addressed a standing room-only crowd at the 31st Annual JP Morgan Healthcare Conference in San Francisco.